IMUGENE LIMITED - Announcements

0.00%

1.5¢

Market Cap $112.0M

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Announcements

Filter Results

All Price Sensitive Only

IMU	Change of Director's Interest Notice - AH		17/12/20	227.52KB	Share
IMU	Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial	PRICE SENSITIVE	17/12/20	136.02KB	Share
IMU	Appendix 3G		16/12/20	339.18KB	Share
IMU	Appendix 2A		16/12/20	375.43KB	Share
IMU	Proposed issue of Securities - IMU		16/12/20	25.24KB	Share
IMU	Changes to Executive Chairman Remuneration		16/12/20	100.61KB	Share
IMU	Imugene Receives $4.82 million R&D Tax Incentive	PRICE SENSITIVE	10/12/20	129.13KB	Share
IMU	Appendix 2A and 708A Notice		09/12/20	4.8MB	Share
IMU	Proposed issue of Securities - IMU		09/12/20	27.1KB	Share
IMU	Change of Director's Interest Notice - CW		08/12/20	174.18KB	Share
IMU	Appendix 3G		03/12/20	622.39KB	Share
IMU	Appendix 2A		01/12/20	470.21KB	Share
IMU	Proposed issue of Securities - IMU		01/12/20	28.04KB	Share
IMU	Imugene First Patient Dosed in PD1-VAXX Clinical Trial	PRICE SENSITIVE	01/12/20	120.02KB	Share
IMU	Appendix 2A		27/11/20	382.9KB	Share
IMU	Appendix 2A		24/11/20	375.95KB	Share
IMU	Proposed issue of Securities - IMU		24/11/20	27.27KB	Share
IMU	Results of Meeting		24/11/20	104.82KB	Share
IMU	Investor Presentation		24/11/20	1.48MB	Share
IMU	AGM Presentation		24/11/20	1.11MB	Share
IMU	Imugene HER Vaxx shows positive Overall Survival in trial	PRICE SENSITIVE	23/11/20	134.83KB	Share
IMU	Release of Securities from Escrow		18/11/20	95.87KB	Share
IMU	Appendix 2A		17/11/20	376.08KB	Share
IMU	Proposed issue of Securities - IMU		17/11/20	27.27KB	Share
IMU	Proposed issue of Securities - IMU		10/11/20	27.27KB	Share
IMU	Appendix 2A		10/11/20	376.15KB	Share
IMU	Appendix 2A		04/11/20	622.66KB	Share
IMU	Proposed issue of Securities - IMU		04/11/20	27.27KB	Share
IMU	Becoming a substantial holder		04/11/20	5.68MB	Share
IMU	Letter to IMUOA Optionholders		02/11/20	911.51KB	Share
IMU	Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA	PRICE SENSITIVE	02/11/20	111.65KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/20	366.05KB	Share
IMU	Appendix 2A		22/10/20	375.98KB	Share
IMU	Proposed issue of Securities - IMU		22/10/20	27.27KB	Share
IMU	Notice of Annual General Meeting/Proxy Form		21/10/20	2.33MB	Share
IMU	Appendix 2A		15/10/20	376.23KB	Share
IMU	Proposed issue of Securities - IMU		15/10/20	27.26KB	Share
IMU	Appendix 2A		07/10/20	376.4KB	Share
IMU	Proposed issue of Securities - IMU		07/10/20	27.27KB	Share
IMU	Imugene Immunotherapy Combination Patent Granted in US	PRICE SENSITIVE	02/10/20	133.51KB	Share
IMU	Letter to IMUOA & IMUOB Option Share Holders		30/09/20	916.34KB	Share
IMU	Imugene appoints Dr Rita Laeufle as Chief Medical Officer		30/09/20	136.99KB	Share
IMU	Appendix 2A		23/09/20	375.88KB	Share
IMU	Proposed issue of Securities - IMU		23/09/20	27.28KB	Share
IMU	Appendix 2A		09/09/20	415.75KB	Share
IMU	Proposed issue of Securities - IMU		09/09/20	24.27KB	Share
IMU	Imugene Secures $5.7 million Option Underwriting Agreement	PRICE SENSITIVE	09/09/20	144.01KB	Share
IMU	Imugene Receives PD1-VAXX Ethics Trial Approval in USA	PRICE SENSITIVE	03/09/20	143.66KB	Share
IMU	Appendix 2A		01/09/20	369KB	Share
IMU	Proposed issue of Securities - IMU		01/09/20	25.24KB	Share
IMU	Appendix 4G		31/08/20	182.78KB	Share
IMU	Corporate Governance Statement		31/08/20	190.29KB	Share
IMU	Appendix 4E & Annual Report to shareholders	PRICE SENSITIVE	31/08/20	4.81MB	Share
IMU	Appendix 2A		25/08/20	811.9KB	Share
IMU	Proposed issue of Securities - IMU		25/08/20	25.24KB	Share
IMU	Imugene Receives Third PD1-VAXX Ethics Trial Approval	PRICE SENSITIVE	21/08/20	126.29KB	Share
IMU	Appendix 2A		18/08/20	813.28KB	Share
IMU	Proposed issue of Securities - IMU		18/08/20	25.24KB	Share
IMU	Change of Director's Interest Notice - CW		12/08/20	170.84KB	Share
IMU	Change of Director's Interest Notice - CW & AH		07/08/20	200.4KB	Share
IMU	Letter to IMUOA Option Share Holders		07/08/20	275.67KB	Share
IMU	Imugene Receives Clinical Guidance from US FDA for Vaxinia	PRICE SENSITIVE	06/08/20	142.12KB	Share
IMU	Change of Director's Interest Notice - LC		05/08/20	326.69KB	Share
IMU	CEO and Managing Director increases shareholding in Imugene		05/08/20	105.69KB	Share
IMU	Appendix 2A and 708A Notice		05/08/20	1.04MB	Share
IMU	Proposed issue of Securities - IMU		04/08/20	31.21KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/20	408.9KB	Share
IMU	Imugene Receives Second PD1-VAXX Ethics Trial Approval	PRICE SENSITIVE	17/07/20	145.69KB	Share
IMU	Imugene Receives Ethics Approval to Start PD1-VAXX Trial	PRICE SENSITIVE	14/07/20	145.97KB	Share
IMU	New mimotope cancer vaccine results published		28/05/20	143.42KB	Share
IMU	Release of Securities from Escrow		15/05/20	260.75KB	Share
IMU	Imugene HER-Vaxx Phase 2 Clinical Update	PRICE SENSITIVE	04/05/20	114.71KB	Share
IMU	IMU Presents Vaxinia Clinical Plan at AACR Annual Meeting		27/04/20	128.02KB	Share
IMU	IMU Presents PD1-Vaxx Clinical Plan at AACR Annual Meeting		27/04/20	129.21KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/20	684.52KB	Share
IMU	Change of Director's Interest Notice - LR		30/03/20	167.84KB	Share
IMU	Change of Director's Interest Notice - CW		25/03/20	169.78KB	Share
IMU	Change of Director's Interest Notice - CW		18/03/20	182.4KB	Share
IMU	Change of Director's Interest Notice - LC		17/03/20	170.2KB	Share
IMU	Change of Director's Interest Notice - LC		13/03/20	168.87KB	Share
IMU	Change of Director's Interest Notice - CW		11/03/20	171.58KB	Share
IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/20	5.84MB	Share
IMU	Ceasing to be a substantial holder		13/02/20	87.8KB	Share
IMU	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	348.47KB	Share
IMU	Imugene PD1-Vaxx Immunotherapy Update	PRICE SENSITIVE	28/01/20	138.09KB	Share
IMU	Imugene HER-Vaxx Immunotherapy Patent Granted in US	PRICE SENSITIVE	14/01/20	123.55KB	Share
IMU	Completion of Less Than Marketable Parcel Sale		24/12/19	97.24KB	Share
IMU	Appendix 3B and Required LR 3.10.5A Information		06/12/19	564.42KB	Share
IMU	Imugene appoints Dr R Auer to Oncolytic Virotherapy SAB		05/12/19	156.53KB	Share
IMU	Prospectus	PRICE SENSITIVE	02/12/19	556.91KB	Share
IMU	Investor Presentation		02/12/19	3.07MB	Share
IMU	Imugene Share Placement to raise $24.6 million	PRICE SENSITIVE	02/12/19	134.16KB	Share
IMU	Change of Director's Interest Notice - PH		28/11/19	218.65KB	Share
IMU	Trading Halt	PRICE SENSITIVE	28/11/19	360.08KB	Share
IMU	Appendix 3B and 708A Notice		28/11/19	500.45KB	Share
IMU	Change of Director's Interest Notice - CW		27/11/19	171.01KB	Share
IMU	CF33 Oncolytic Virus GMP Manufacturing Update		25/11/19	84.79KB	Share
IMU	Imugene appoints Prof Prasad S Adusumilli of MSKCC to OV SAB		20/11/19	130.96KB	Share
IMU	Change of Director's Interest Notice - JE		19/11/19	168.81KB	Share
IMU	Change of Director's Interest Notice - LR		19/11/19	169.1KB	Share

IMU Change of Director's Interest Notice - AH
17/12/20		227.52KB	Share
IMU Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial
17/12/20	PRICE SENSITIVE	136.02KB	Share
IMU Appendix 3G
16/12/20		339.18KB	Share
IMU Appendix 2A
16/12/20		375.43KB	Share
IMU Proposed issue of Securities - IMU
16/12/20		25.24KB	Share
IMU Changes to Executive Chairman Remuneration
16/12/20		100.61KB	Share
IMU Imugene Receives $4.82 million R&D Tax Incentive
10/12/20	PRICE SENSITIVE	129.13KB	Share
IMU Appendix 2A and 708A Notice
09/12/20		4.8MB	Share
IMU Proposed issue of Securities - IMU
09/12/20		27.1KB	Share
IMU Change of Director's Interest Notice - CW
08/12/20		174.18KB	Share
IMU Appendix 3G
03/12/20		622.39KB	Share
IMU Appendix 2A
01/12/20		470.21KB	Share
IMU Proposed issue of Securities - IMU
01/12/20		28.04KB	Share
IMU Imugene First Patient Dosed in PD1-VAXX Clinical Trial
01/12/20	PRICE SENSITIVE	120.02KB	Share
IMU Appendix 2A
27/11/20		382.9KB	Share
IMU Appendix 2A
24/11/20		375.95KB	Share
IMU Proposed issue of Securities - IMU
24/11/20		27.27KB	Share
IMU Results of Meeting
24/11/20		104.82KB	Share
IMU Investor Presentation
24/11/20		1.48MB	Share
IMU AGM Presentation
24/11/20		1.11MB	Share
IMU Imugene HER Vaxx shows positive Overall Survival in trial
23/11/20	PRICE SENSITIVE	134.83KB	Share
IMU Release of Securities from Escrow
18/11/20		95.87KB	Share
IMU Appendix 2A
17/11/20		376.08KB	Share
IMU Proposed issue of Securities - IMU
17/11/20		27.27KB	Share
IMU Proposed issue of Securities - IMU
10/11/20		27.27KB	Share
IMU Appendix 2A
10/11/20		376.15KB	Share
IMU Appendix 2A
04/11/20		622.66KB	Share
IMU Proposed issue of Securities - IMU
04/11/20		27.27KB	Share
IMU Becoming a substantial holder
04/11/20		5.68MB	Share
IMU Letter to IMUOA Optionholders
02/11/20		911.51KB	Share
IMU Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA
02/11/20	PRICE SENSITIVE	111.65KB	Share
IMU Appendix 4C - quarterly
27/10/20	PRICE SENSITIVE	366.05KB	Share
IMU Appendix 2A
22/10/20		375.98KB	Share
IMU Proposed issue of Securities - IMU
22/10/20		27.27KB	Share
IMU Notice of Annual General Meeting/Proxy Form
21/10/20		2.33MB	Share
IMU Appendix 2A
15/10/20		376.23KB	Share
IMU Proposed issue of Securities - IMU
15/10/20		27.26KB	Share
IMU Appendix 2A
07/10/20		376.4KB	Share
IMU Proposed issue of Securities - IMU
07/10/20		27.27KB	Share
IMU Imugene Immunotherapy Combination Patent Granted in US
02/10/20	PRICE SENSITIVE	133.51KB	Share
IMU Letter to IMUOA & IMUOB Option Share Holders
30/09/20		916.34KB	Share
IMU Imugene appoints Dr Rita Laeufle as Chief Medical Officer
30/09/20		136.99KB	Share
IMU Appendix 2A
23/09/20		375.88KB	Share
IMU Proposed issue of Securities - IMU
23/09/20		27.28KB	Share
IMU Appendix 2A
09/09/20		415.75KB	Share
IMU Proposed issue of Securities - IMU
09/09/20		24.27KB	Share
IMU Imugene Secures $5.7 million Option Underwriting Agreement
09/09/20	PRICE SENSITIVE	144.01KB	Share
IMU Imugene Receives PD1-VAXX Ethics Trial Approval in USA
03/09/20	PRICE SENSITIVE	143.66KB	Share
IMU Appendix 2A
01/09/20		369KB	Share
IMU Proposed issue of Securities - IMU
01/09/20		25.24KB	Share
IMU Appendix 4G
31/08/20		182.78KB	Share
IMU Corporate Governance Statement
31/08/20		190.29KB	Share
IMU Appendix 4E & Annual Report to shareholders
31/08/20	PRICE SENSITIVE	4.81MB	Share
IMU Appendix 2A
25/08/20		811.9KB	Share
IMU Proposed issue of Securities - IMU
25/08/20		25.24KB	Share
IMU Imugene Receives Third PD1-VAXX Ethics Trial Approval
21/08/20	PRICE SENSITIVE	126.29KB	Share
IMU Appendix 2A
18/08/20		813.28KB	Share
IMU Proposed issue of Securities - IMU
18/08/20		25.24KB	Share
IMU Change of Director's Interest Notice - CW
12/08/20		170.84KB	Share
IMU Change of Director's Interest Notice - CW & AH
07/08/20		200.4KB	Share
IMU Letter to IMUOA Option Share Holders
07/08/20		275.67KB	Share
IMU Imugene Receives Clinical Guidance from US FDA for Vaxinia
06/08/20	PRICE SENSITIVE	142.12KB	Share
IMU Change of Director's Interest Notice - LC
05/08/20		326.69KB	Share
IMU CEO and Managing Director increases shareholding in Imugene
05/08/20		105.69KB	Share
IMU Appendix 2A and 708A Notice
05/08/20		1.04MB	Share
IMU Proposed issue of Securities - IMU
04/08/20		31.21KB	Share
IMU Appendix 4C - quarterly
27/07/20	PRICE SENSITIVE	408.9KB	Share
IMU Imugene Receives Second PD1-VAXX Ethics Trial Approval
17/07/20	PRICE SENSITIVE	145.69KB	Share
IMU Imugene Receives Ethics Approval to Start PD1-VAXX Trial
14/07/20	PRICE SENSITIVE	145.97KB	Share
IMU New mimotope cancer vaccine results published
28/05/20		143.42KB	Share
IMU Release of Securities from Escrow
15/05/20		260.75KB	Share
IMU Imugene HER-Vaxx Phase 2 Clinical Update
04/05/20	PRICE SENSITIVE	114.71KB	Share
IMU IMU Presents Vaxinia Clinical Plan at AACR Annual Meeting
27/04/20		128.02KB	Share
IMU IMU Presents PD1-Vaxx Clinical Plan at AACR Annual Meeting
27/04/20		129.21KB	Share
IMU Appendix 4C - quarterly
24/04/20	PRICE SENSITIVE	684.52KB	Share
IMU Change of Director's Interest Notice - LR
30/03/20		167.84KB	Share
IMU Change of Director's Interest Notice - CW
25/03/20		169.78KB	Share
IMU Change of Director's Interest Notice - CW
18/03/20		182.4KB	Share
IMU Change of Director's Interest Notice - LC
17/03/20		170.2KB	Share
IMU Change of Director's Interest Notice - LC
13/03/20		168.87KB	Share
IMU Change of Director's Interest Notice - CW
11/03/20		171.58KB	Share
IMU Half Yearly Report and Accounts
26/02/20	PRICE SENSITIVE	5.84MB	Share
IMU Ceasing to be a substantial holder
13/02/20		87.8KB	Share
IMU Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	348.47KB	Share
IMU Imugene PD1-Vaxx Immunotherapy Update
28/01/20	PRICE SENSITIVE	138.09KB	Share
IMU Imugene HER-Vaxx Immunotherapy Patent Granted in US
14/01/20	PRICE SENSITIVE	123.55KB	Share
IMU Completion of Less Than Marketable Parcel Sale
24/12/19		97.24KB	Share
IMU Appendix 3B and Required LR 3.10.5A Information
06/12/19		564.42KB	Share
IMU Imugene appoints Dr R Auer to Oncolytic Virotherapy SAB
05/12/19		156.53KB	Share
IMU Prospectus
02/12/19	PRICE SENSITIVE	556.91KB	Share
IMU Investor Presentation
02/12/19		3.07MB	Share
IMU Imugene Share Placement to raise $24.6 million
02/12/19	PRICE SENSITIVE	134.16KB	Share
IMU Change of Director's Interest Notice - PH
28/11/19		218.65KB	Share
IMU Trading Halt
28/11/19	PRICE SENSITIVE	360.08KB	Share
IMU Appendix 3B and 708A Notice
28/11/19		500.45KB	Share
IMU Change of Director's Interest Notice - CW
27/11/19		171.01KB	Share
IMU CF33 Oncolytic Virus GMP Manufacturing Update
25/11/19		84.79KB	Share
IMU Imugene appoints Prof Prasad S Adusumilli of MSKCC to OV SAB
20/11/19		130.96KB	Share
IMU Change of Director's Interest Notice - JE
19/11/19		168.81KB	Share
IMU Change of Director's Interest Notice - LR
19/11/19		169.1KB	Share

REFRESH

First 4 5 6 7 8

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.5¢		Change 0.000(0.00%)		Mkt cap ! $112.0M

Open	High	Low	Value	Volume
1.5¢	1.6¢	1.4¢	$125.4K	8.369M

Buyers (Bids)

No.	Vol.	Price($)
76	17029463	1.4¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	1061875	3

View Market Depth

No.	Vol.	Price($)
67	15122749	0.014
35	10959455	0.013
40	8162244	0.012
13	3263001	0.011
30	6569728	0.010

Price($)	Vol.	No.
0.015	873992	2
0.016	10695661	30
0.017	6170154	16
0.018	6533023	29
0.019	6839697	18

Last trade - 16.10pm 13/06/2025 (20 minute delay)

IMU (ASX) Chart

IMUGENE LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories